Annals of hepatology最新文献

{"title":"A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined comprehensive treatment for hepatocellular carcinoma.","authors":"Bingzheng Yan, Zhikai Yang, Cong Liu, Haifang Wang, Yuguo Zhang, Dawei Yang","doi":"10.1016/j.aohep.2025.102106","DOIUrl":"10.1016/j.aohep.2025.102106","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with intra-arterial bevacizumab infusion in patients with advanced hepatocellular carcinoma (HCC).</p><p><strong>Patients and methods: </strong>In this prospective randomized controlled trial, 120 patients with advanced HCC (stages Ib-IIIb) were enrolled between March 2021 and October 2023 and randomized to receive TACE alone (control group, n = 60) or TACE plus intra-arterial bevacizumab (combined group, n = 60). Tumor perfusion parameters were assessed via dynamic contrast-enhanced MRI (DCE-MRI), while VEGF and SDF-1 levels were measured using ELISA. Efficacy, safety, and adverse events were compared between groups. Efficacy analyses for tumor response were based on 58 patients per group with complete imaging data.</p><p><strong>Results: </strong>The combined group exhibited significant reductions in DCE-MRI parameters, including transfer coefficient, blood flow, and plasma volume (all P < 0.05). Complete response (CR) rates were 0 % in both groups (P > 0.05). Partial response (PR) rates were higher in the combined group (27.6 % vs. 6.9 %, P < 0.05), as were stable disease (SD) rates (60.3 % vs. 34.5 %, P < 0.05). Total disease control (CR+PR+SD) was significantly improved in the combined group (87.9 % vs. 41.4 %, P < 0.05). Liver/kidney function and adverse event rates (e.g., hypertension, 8.3 % in combined group) were comparable between groups (P > 0.05), though proteinuria was more frequent in the combined group (6.7 % vs. 0 %, P = 0.043).</p><p><strong>Conclusions: </strong>Intra-arterial bevacizumab combined with TACE enhances tumor response and disease control in advanced HCC without a substantial increase in overall toxicity, providing a promising locoregional anti-angiogenic strategy.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102106"},"PeriodicalIF":4.4,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide.","authors":"Mikkel Parsberg Werge, Adrian McCann, Elias Badal Rashu, Shi Min Lam, Liv Eline Hetland, Mira Thing, Puria Nabilou, Anders Ellekaer Junker, Jenny Norlin, Sanne Veidal, Dorte Holst, Anne Bugge, Birgitte Martine Viuff, Henning Hvid, Kristian M Bendtsen, Gianluca Mazzoni, Lea Moerch Harder, Mogens Vyberg, Reza Serizawa, Flemming Bendtsen, Per Magne Ueland, Elisabeth Douglas Galsgaard, Nicolai J Wewer Albrechtsen, Lise Lotte Gluud","doi":"10.1016/j.aohep.2025.102107","DOIUrl":"10.1016/j.aohep.2025.102107","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Disruptions in one-carbon metabolism (OCM) have been linked to cardiometabolic diseases. We evaluated alterations in OCM metabolites and enzymes and the impact of semaglutide in MASLD.</p><p><strong>Materials and methods: </strong>Using targeted metabolomics and bulk-transcriptomics, we analyzed components of OCM in plasma samples and liver biopsies from MASLD patients (n = 100 with F0-F4 fibrosis, 51% type 2 diabetes) and healthy controls (n = 50). Untargeted metabolomics and transcriptomics were used to analyze plasma and liver specimens from mice with diet-induced obesity and steatohepatitis (DIO-MASH) treated with vehicle or semaglutide compared with chow for 12 weeks.</p><p><strong>Results: </strong>In patients with MASLD vs healthy controls, changes in the concentrations of folate and pyridoxal 5'-phosphate (vitamin B6), betaine, serine, and glycine suggested alteration to the activity of the transsulfuration pathway as well as the methionine and folate cycles. Increased concentrations of metabolites related to enhanced homocysteine conversion and elevated glutamate were also observed. These findings were supported by corresponding alterations in the activity of key enzymes. Similar patterns were identified in comparisons of patients with significant vs no/mild fibrosis and in DIO-MASH mice vs chow. Treatment with semaglutide led to reductions in body weight, hepatic inflammation, and fibrosis and largely reversed the metabolic and gene expression changes observed in DIO-MASH mice.</p><p><strong>Conclusions: </strong>MASLD may be linked to alterations in key metabolites and enzymes involved in OCM. The changes in humans were replicated in a MASLD mouse model, and reversal was found after treatment with semaglutide.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102107"},"PeriodicalIF":4.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The story of hepatitis E virus infection and chronic kidney disease without liver damage.","authors":"Addi P Figueroa-Miranda, Edgar D Copado-Villagrana, Nora A Fierro","doi":"10.1016/j.aohep.2025.101946","DOIUrl":"https://doi.org/10.1016/j.aohep.2025.101946","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101946"},"PeriodicalIF":4.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: A United States cohort.","authors":"Leandro Sierra, Bryan Ferrigno, Ana Marenco-Flores, Marwan Alsaqa, Natalia Rojas, Romelia Barba, Daniela Goyes, Esli Medina-Morales, Behnam Saberi, Vilas Patwardhan, Alan Bonder","doi":"10.1016/j.aohep.2025.101945","DOIUrl":"10.1016/j.aohep.2025.101945","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Autoimmune liver diseases (AILDs) affect health-related quality of life (HRQOL). This seven-year, prospective study analyzes the impact of AILDs on HRQOL.</p><p><strong>Materials and methods: </strong>We collected the Chronic Liver Disease Questionnaire (CLDQ) and the EuroQol-5 Dimension (EQ-5D), totaling 1214 responses from 466 AILD patients (2017-2024). CLDQ was compared via Kruskal-Wallis. Chi-square and ANOVA were used for EQ-5D frequencies and means. Multivariate (MVA) regressions identified CLDQ symptom predictors. Tobit regression analyzed EQ-5D UI. Pearson's correlation assessed CLDQ-EQ-5D association.</p><p><strong>Results: </strong>We included 230 AIH, 118 PSC, and 118 PBC patients. Total CLDQ was lower in PBC compared to AIH and PSC (5.25, 5.54, 5.59; P < 0.001), as was EQ-5D UI (0.85, 0.88, 0.88; P < 0.001). In CLDQ, PBC domains were significantly worse except Worry. Fatigue scored lowest in PBC, with tiredness, decreased energy, and daytime sleepiness as the most debilitating symptoms (3.91, 4.20, 4.27; P < 0.001). In EQ-5D, every item was worse in PBC except anxiety/depression, with pain being worst (P < 0.001). CLDQ MVA identified female (β: -0.26), Hispanic race (β: -0.31), and MASLD/MASH (β: -0.32) as predictors of symptom worsening (P < 0.05). Tobit regression for EQ-5D revealed female (β: -0.03), MASLD/MASH (β: -0.07), and cirrhosis (β: -0.06) as symptom severity predictors (P < 0.05). Pearson's correlation showed that CLDQ and EQ-5D in AILD were strongly correlated (r = 0.63; P < 0.001).</p><p><strong>Conclusions: </strong>Among AILDs, PBC most severely impacts HRQOL, especially in tiredness, sleepiness, concentration, and pain. Female, Hispanic, and MASLD overlap patients are disproportionately affected. Both CLDQ and EQ-5D predict symptom severity, but CLDQ identifies more predictors and stronger associations.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101945"},"PeriodicalIF":4.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we measuring fibrosis or just fluctuations? Rethinking liver stiffness measurement trajectories in chronic hepatitis B.","authors":"Gokhan Koker","doi":"10.1016/j.aohep.2025.101942","DOIUrl":"10.1016/j.aohep.2025.101942","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101942"},"PeriodicalIF":4.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Hepatocellular carcinoma surveillance: Current challenges in Latin America”","authors":"Josefina Pages ,&nbsp;Manuel Mendizabal ,&nbsp;Graciela Castro-Narro ,&nbsp;Jose María Menéndez ,&nbsp;Oscar Beltran ,&nbsp;Leonardo Gomes Da Fonseca ,&nbsp;Jaime Poniachik Teller ,&nbsp;Marcos Girala ,&nbsp;Daniel Fabricio Alarcon Cano ,&nbsp;Federico Piñero ,&nbsp;special group of interest of liver cancer from the American Association Study for Liver Diseases (ALEH)","doi":"10.1016/j.aohep.2025.101935","DOIUrl":"10.1016/j.aohep.2025.101935","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the most common primary liver cancer, predominantly linked with cirrhosis and chronic hepatitis B. In Latin America, disparities in healthcare access complicate HCC management. A recent expert meeting emphasized the importance of identifying at-risk populations for effective screening and surveillance, underlining the need for structured routine programs.</div><div>Early detection of HCC improves outcomes and increases survival rates. Surveillance programs are essential, yet access to healthcare and treatment varies significantly across Latin America, making timely diagnosis and intervention challenging. Additionally, recent shifts in disease etiology, notably the rising prevalence of MASLD, further complicate HCC detection.</div><div>Effective HCC surveillance relies on cost-efficient diagnostic tools. Ultrasound is the main screening method, though it has moderate sensitivity. In obese patients, achieving adequate visualization is particularly difficult. Combining ultrasound with alpha-fetoprotein (AFP) improves diagnostic accuracy. Biomarkers such as AFP are commonly used to diagnose and monitor HCC, but their predictive value remains limited. Integrating biomarkers with ultrasound or other novel markers may enhance detection; however, further research is necessary to validate these strategies.</div><div>In conclusion, HCC surveillance remains a significant challenge in our region. A comprehensive, multifaceted approach is needed to improve early detection and clinical outcomes.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101935"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study”","authors":"Xiaohan Zhou,&nbsp;Yani Wang","doi":"10.1016/j.aohep.2025.101934","DOIUrl":"10.1016/j.aohep.2025.101934","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101934"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical commentary on camrelizumab-based triple therapy for unresectable hepatocellular carcinoma","authors":"Ibrahim Nagmeldin Hassan","doi":"10.1016/j.aohep.2025.101940","DOIUrl":"10.1016/j.aohep.2025.101940","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101940"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile","authors":"Maria Spencer-Sandino ,&nbsp;Franco Godoy ,&nbsp;Laura Huidobro ,&nbsp;Danilo Alvares ,&nbsp;Francisco Cruz ,&nbsp;Claudia Marco ,&nbsp;Macarena Garrido ,&nbsp;Daniel Cabrera ,&nbsp;Juan Pablo Arab ,&nbsp;Marco Arrese ,&nbsp;Francisco Barrera ,&nbsp;Catterina Ferreccio","doi":"10.1016/j.aohep.2025.101919","DOIUrl":"10.1016/j.aohep.2025.101919","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>This study aims to assess the performance of Steatotic Liver Disease (SLD) criteria in identifying liver steatosis compared to the NAFLD and MAFLD definitions in an agricultural population in Chile.</div></div><div><h3>Patients and Methods</h3><div>We performed a cross-sectional analysis on the MAUCO cohort, composed of 9,013 individuals aged 38 to 74. Health conditions, socio-demographics, anthropometrics, hepatic ultrasonography, blood pressure, and biological samples were obtained. Participants were classified as NAFLD, MAFLD, or any of the five SLD categories: Metabolic dysfunction-associated steatosis liver disease (MASLD), Metabolic and Alcohol-Associated Liver Disease (MetALD), Alcohol-Associated Liver Disease (ALD), Specific aetiologies, and Cryptogenic. The Framingham cardiovascular risk score and BARD liver fibrosis score were used to assess clinical relevance.</div></div><div><h3>Results</h3><div>Liver steatosis was present in 4,082 participants (45%); SLD criteria captured an additional 176 individuals not classified under NAFLD and 103 not included under MAFLD definition. The main SLD subgroups were MASLD (95%), MetALD (1.9%) and ALD (1.3%). Individuals classified in the MetALD and ALD subgroups exhibited more severe liver steatosis and a higher cardiovascular risk. Notably, participants categorized under specific etiologies and cryptogenic subgroups were younger and had a higher risk for liver fibrosis.</div></div><div><h3>Conclusions</h3><div>The study reveals that SLD offers a more inclusive classification to identify high-risk individuals in the Chilean population, capturing cases that could be missed by NAFLD or MAFLD definitions by using the same resources.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101919"},"PeriodicalIF":3.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management","authors":"Victoria Mainardi ,&nbsp;Josefina Pages ,&nbsp;Josemaría Menendez ,&nbsp;Rodrigo Zapata ,&nbsp;Luis Antonio Díaz ,&nbsp;Sebastian Marciano ,&nbsp;Fernando Cairo ,&nbsp;Martin Padilla-Machaca ,&nbsp;Laura Tenorio ,&nbsp;Alvaro Urzua ,&nbsp;Lucia Navarro ,&nbsp;Nicolas Dominguez ,&nbsp;Pablo Coste ,&nbsp;Manuel Mendizabal ,&nbsp;Jorge Martinez ,&nbsp;Sergio Lopez ,&nbsp;Adriana Varon ,&nbsp;Alfeu de Medeiros Fleck jr ,&nbsp;Jhon Abad Gonzalez ,&nbsp;Juan Carlos Restrepo ,&nbsp;Alejandra Villamil","doi":"10.1016/j.aohep.2025.101939","DOIUrl":"10.1016/j.aohep.2025.101939","url":null,"abstract":"<div><div>Liver transplantation (LT) is the standard of care therapy for patients with decompensated cirrhosis, early-stage hepatocellular carcinoma, acute liver failure, and other expanding indications. Latin America is a highly heterogeneous region characterized by an uneven distribution of socio-economic conditions and irregular access to health resources, and consequently LT activity varies across the region. This current guidance on preoperative care in LT represents a collaborative effort to assess and standardize preoperative evaluation of liver transplant candidates in Latin America. It is the first position paper of the special interest group on LT of the Latin American Association for the Study of the Liver (ALEH), which provides evidence-based comprehensive recommendations regarding whom to refer, how to assess LT candidates and how to manage patients on the waiting list, taking into consideration their applicability in Latin America.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101939"},"PeriodicalIF":4.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}